DelveInsight’s “Open Angle Glaucoma Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Open Angle Glaucoma, historical and forecasted epidemiology as well as the Open Angle Glaucoma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
The Open Angle Glaucoma market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
To Know in detail about the Open Angle Glaucoma market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Open Angle Glaucoma Market Insights
Open Angle Glaucoma Overview
Glaucoma is a disease that damages the eye’s optic nerve. It usually happens when fluid builds up in the front part of the eye. That extra fluid increases the pressure in eye, damaging the optic nerve. The condition is a leading cause of blindness for people over 60 years old. But blindness from glaucoma can often be prevented with early treatment.
Some of the key facts of the Open Angle Glaucoma Market Report:
- The Open Angle Glaucoma market size was valued at USD 4,500 Million in the year 2021and is anticipated to grow with a significant CAGR during the study period (2019-2032)
- The total diagnosed prevalence of Glaucoma in 7MM was estimated to be ~11,048,000 cases in 2021 and is expected to increase during the study period (2019–2032)
- The total diagnosed prevalent population of Open angle Glaucoma (OAG) and Close Angle Glaucoma in the US was estimated to be ~3,119,000 cases and ~347,000 cases in 2021 and is expected to increase during the study period (2019-2032)
- Total diagnosed prevalence of Glaucoma in the US was estimated to be ~3,466,000 cases in 2021 and is expected to increase during the study period (2019–2032)
- Key Open Angle Glaucoma Companies: SPARC, TearClear,Kowa, AbbVie Inc., Aerie Pharmaceuticals Inc, Alcon Inc., Bausch Health Co Inc, D.Western Therapeutics Institute Inc, Hikma Pharmaceuticals Plc, Laboratories Sophia, Merck and Co. Inc., Nicox SA, Novartis AG, Ocuphire Pharma Inc, Otsuka Pharmaceutical Co. Ltd., Pfizer Inc., PharmaMar SA, Santen Pharmaceutical Co. Ltd., Sun Pharmaceutical Industries Ltd, Taro Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., Viatris Inc., and others
- Key Open Angle Glaucoma Therapies: PDP-716, TC-002, Omidenepagisopropyl, DE-117, DE-130A, Sepetaprost (DE-126/ONO9054), NCX-470, Nyxol, K-232, and others
- The Glaucoma epidemiology based on gender analyzed that among the gender-specific prevalent cases, females are affected more with glaucoma than male
Get a Free sample for the Open Angle Glaucoma Market Report –
https://www.delveinsight.com/sample-request/open-angle-glaucoma-market
Key benefits of the Open Angle Glaucoma Market report:
- Open Angle Glaucoma market report covers a descriptive overview and comprehensive insight of the Open Angle Glaucoma Epidemiology and Open Angle Glaucoma market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
- The Open Angle Glaucoma market report provides insights on the current and emerging therapies.
- Open Angle Glaucoma market report provides a global historical and forecasted market covering drug outreach in 7MM.
- The Open Angle Glaucoma market report offers an edge that will help develop business strategies by understanding trends shaping and driving the Open Angle Glaucoma market.
Download the report to understand which factors are driving Open Angle Glaucoma epidemiology trends @ Open Angle Glaucoma Epidemiological Insights
Open Angle Glaucoma Market
The dynamics of the Open Angle Glaucoma market are anticipated to change in the coming years owing to the expected launch of emerging therapies and others during the forecasted period 2019-2032.
“The mainstay of the treatment for Open Angle Glaucoma is to improve quality of life. There are therapies that are undergoing investigational analysis for the same. Pharmaceutical giants like Santen, SPARC, Bausch and Lomb, and others have their candidates in the pipeline.”
Open Angle Glaucoma Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Open Angle Glaucoma Epidemiology Segmentation:
The Open Angle Glaucoma market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:
- Total Prevalence of Open Angle Glaucoma
- Prevalent Cases of Open Angle Glaucoma by severity
- Gender-specific Prevalence of Open Angle Glaucoma
- Diagnosed Cases of Episodic and Chronic Open Angle Glaucoma
Open Angle Glaucoma Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Open Angle Glaucoma market or expected to get launched during the study period. The analysis covers Open Angle Glaucoma market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Open Angle Glaucoma Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Discover more about therapies set to grab major Open Angle Glaucoma market share @ Open Angle Glaucoma market forecast
Open Angle Glaucoma Therapies and Key Companies
- PDP-716: SPARC
- TC-002: TearClear
- Omidenepagisopropyl/DE-117: Santen Pharmaceutical
- DE-130A: Santen Pharmaceutical
- Sepetaprost (DE-126/ONO9054): Santen Pharmaceutical
- NCX-470: Nicox Ophthalmics
- Nyxol: Ocuphire Pharma
- K-232: Kowa
Open Angle Glaucoma Market Drivers
- New drug-delivery systems offer the hope of improved therapeutic outcomes by dealing with the problem of patient compliance and therapeutic adherence
- With the rise in awareness about the disease and its subtypes, now people are more cautious about glaucoma, its treatment and management options which will promote the glaucoma market
Scope of the Open Angle Glaucoma Market Report
- Study Period: 2019–2032
- Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
- Key Open Angle Glaucoma Companies: SPARC, TearClear,Kowa, AbbVie Inc., Aerie Pharmaceuticals Inc, Alcon Inc., Bausch Health Co Inc, D.Western Therapeutics Institute Inc, Hikma Pharmaceuticals Plc, Laboratories Sophia, Merck and Co. Inc., Nicox SA, Novartis AG, Ocuphire Pharma Inc, Otsuka Pharmaceutical Co. Ltd., Pfizer Inc., PharmaMar SA, Santen Pharmaceutical Co. Ltd., Sun Pharmaceutical Industries Ltd, Taro Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., Viatris Inc., and others
- Key Open Angle Glaucoma Therapies: PDP-716, TC-002, Omidenepagisopropyl, DE-117, DE-130A, Sepetaprost (DE-126/ONO9054), NCX-470, Nyxol, K-232, and others
- Open Angle Glaucoma Therapeutic Assessment: Open Angle Glaucoma current marketed and Open Angle Glaucoma emerging therapies
- Open Angle Glaucoma Market Dynamics: Open Angle Glaucoma market drivers and Open Angle Glaucoma market barriers
- Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
- Open Angle Glaucoma Unmet Needs, KOL’s views, Analyst’s views, Open Angle Glaucoma Market Access and Reimbursement
Open Angle Glaucoma Market Opportunities
- The recent advances in methods for gene-replacement and CRISPR/cas gene-editing support the feasibility of gene based therapies for glaucoma in the relatively near future. Currently, there are no FDA approved gene-based methods for glaucoma
- New diagnostic technologies and tools as well as innovation and modifications in laser/surgical techniques continue to emerge and provide improvement in glaucoma care.
Table of Contents
1. Open Angle Glaucoma Market Report Introduction
2. Executive Summary for Open Angle Glaucoma
3. SWOT analysis of Open Angle Glaucoma
4. Open Angle Glaucoma Patient Share (%) Overview at a Glance
5. Open Angle Glaucoma Market Overview at a Glance
6. Open Angle Glaucoma Disease Background and Overview
7. Open Angle Glaucoma Epidemiology and Patient Population
8. Country-Specific Patient Population of Open Angle Glaucoma
9. Open Angle Glaucoma Current Treatment and Medical Practices
10. Open Angle Glaucoma Unmet Needs
11. Open Angle Glaucoma Emerging Therapies
12. Open Angle Glaucoma Market Outlook
13. Country-Wise Open Angle Glaucoma Market Analysis (2019–2032)
14. Open Angle Glaucoma Market Access and Reimbursement of Therapies
15. Open Angle Glaucoma Market Drivers
16. Open Angle Glaucoma Market Barriers
17. Open Angle Glaucoma Appendix
18. Open Angle Glaucoma Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
To know more about Open Angle Glaucoma treatment, visit @ Open Angle Glaucoma Medications
Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services